LVLjuba Vujanović

Ljuba Vujanović

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ljuba Vujanović has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Atopic dermatitis - novel insights in the immunopathology of the disease

    by Sanja Jakovljevic, Iva Barjaktarovic, Dunja Jakovljevic, Olivera Levakov, Ljuba Vujanovic

    Atopic dermatitis is an inflammatory skin disease that is characterized by the chronic-relapsing course and a pronounced feeling of itching. Altered production of structural proteins, lipids and antimicrobial peptides result in the epidermal impairment leading to the early onset of disease, more severe lesions and a numerous comorbidities. Atopic dermatitis has been recently recognized as a systemic type 2 inflammation by which emerging novel therapeutic modalities reflect sophisticated molecular and immunopathological pathways. The aim of this article is to deliver thorough review of the existing knowledge regarding the most significant immunological aspects of the development and progression of atopic dermatitis.

  • Open Access

    Epidemiological trends of syphilis and the analysis of knowledge and attitudes of future healthcare professionals on its prevention in the autonomous Province of Vojvodina, Serbia

    by Zoran Golušin, Nataša Čapo, Nemanja Maletin, Nikola Denda, Milan Matić, Ljuba Vujanović, Tatjana Roš, Olivera Levakov, Siniša Babović, Mila Crnojević, et al.

    Syphilis remains a growing public health concern, with increasing reported incidence globally. Future healthcare professionals play a key role in preventio


  • Open Access

    miRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as Potential Biomarkers for Atopic Dermatitis

    by Sanja Jakovljevic, Iva Barjaktarovic, Dunja Jakovljevic, Olivera Levakov, Ljuba Vujanovic

    Background/Objectives: Recently, epigenetic mechanisms have been recognized as crucial in atopic dermatitis development. The emphasis of this research was on expanding existing knowledge about the epigenetic aspects of atopic dermatitis, as well as identifying new molecules that could serve as disease biomarkers. Methods: The research was conducted as a cross-sectional study examining two groups: the group with atopic dermatitis (50 patients) and the control group (50 healthy adults). The serum levels of total immunoglobulin E (IgE) and eosinophil count (Eos%) were performed in routine laboratory analyses, and the detection of microRNAs from peripheral blood was performed using RT-PCR. Results: Analysis of selected miRNA expressions in patients with atopic dermatitis and controls revealed that only the expression and the relative expression of miRNA-146a were statistically significantly higher in patients with atopic dermatitis than in the control group (p = 0.042 and p = 0.021, respectively). There was a weak positive correlation between miRNA-146a expression and the eosinophilia/IgE level (r = 0.22 and r = 0.25, respectively). MiRNA-21, miRNA-29b, miRNA-143 and miRNA-223 were significantly upregulated in patients with higher SCORAD (p < 0.001, p < 0.001, p < 0.001 and p = 0.015, respectively). ROC curve analysis revealed the specificity of miRNA-146a as 82% and the sensitivity as 62%. The area under the ROC curve (AUC) was 0.7, indicating its diagnostic potential. Conclusions: Our findings imply that miRNA-146a might serve as a biomarker of atopic dermatitis, suggesting its relevance in the development of the disease, while miRNA-21, miRNA-29b, miRNA-143 and miRNA-223 may have an impact on disease progression. Our findings provide a preliminary basis that should precede validation through larger, multicentric studies and use in diagnostics, targeted personalized treatments and monitoring of treatment efficacy in atopic dermatitis.


  • Open Access

    miRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as Potential Biomarkers for Atopic Dermatitis

    by Sanja Jakovljevic, Iva Barjaktarovic, Dunja Jakovljevic, Olivera Levakov, Ljuba Vujanović

    Background/Objectives: Recently, epigenetic mechanisms have been recognized as crucial in atopic dermatitis development. The emphasis of this research was on ex-panding existing knowledge about the epigenetic aspects of atopic dermatitis, as well as identifying new molecules that could serve as disease biomarkers. Methods: The re-search was conducted as a prospective study examining two groups: the group with atopic dermatitis (50 patients) and the control group (50 healthy adults). The serum levels of total immunoglobulin E (IgE) and eosinophil count (Eos%) were done in rou-tine laboratory analyses, and the detection of microRNAs from peripheral blood was performed using RT-PCR. Results: Analysis of selected miRNA expression in patients with atopic dermatitis and controls revealed that only the expression and the relative expression of miRNA-146a were statistically significantly higher in patients with atopic dermatitis than in the control group (p=0.042 and p=0.021, respectively). There was a weak positive correlation between miRNA-146a expression and the eosinophilia / IgE level (r=0.22 and r=0.25, respectively). The miRNA-21, miRNA-29b, miRNA-143 and miRNA-223 were significantly upregulated in patients with higher SCORAD (p< 0.001, p< 0.001, p< 0.001 and p= 0.015, respectively). ROC curve analysis revealed the specificity of miRNA-146a as 82% and the sensitivity as 62%. The area under the ROC curve (AUC) was 0.7, confirming a valid diagnostic potential. Conclusions: Our find-ings imply that miRNA-146a may be a novel biomarker of atopic dermatitis and might play a specific role in the development of the disease, while miRNA-21, miRNA-29b and miRNA-223 may have an impact on the disease progression. Our study provides findings that can be utilized in future diagnostic applications, targeted personalized treatments and support the monitoring of atopic dermatitis treatment effectiveness.


  • Open Access

    Awareness of Syphilis and Its Prevention Among Medical Students: An Analysis of Knowledge and Attitudes of Future Healthcare Professionals

    by Zoran Golušin, Nikola Denda, Milan Matić, Ljuba Vujanović, Tatjana Roš, Olivera Levakov, Nemanja Maletin

    Background/Objectives : Syphilis is a significant public health issue with a rising incidence, particularly among the MSM population. As future healthcare professionals, medical science students play a crucial role in prevention and treatment. The aim of this study was to assess the knowledge and attitudes of MFNS students regarding syphilis and prevention. Methods : A cross-sectional study was conducted from December 1 to 30, 2024 using a survey structured questionnaire. Results: The average age of participants was 22.22 years, with the majority being women (74.43%). Medical students demonstrated significantly higher knowledge levels about syphilis compared to students from other programs (36.99% vs. 8.03%; p<0.001). Attendance at education sessions on sexually transmitted infections was associated with better test results (p<0.001). Attendance at educational sessions on sexually transmitted infections was strongly associated with better test results (p<0.001), as well as with a higher likelihood of achieving a high number of correct answers (OR = 5.98, 95% CI 3.41–10.49; p<0.001). Most participants (69.10%) identified stigma as a barrier to seeking medical assistance. Conclusions : Medical students demonstrated better knowledge and attitudes toward syphilis prevention compared to their peers from other study programs. However, deficiencies were noted in practical skills and confidence in providing patient counseling. The results highlight the need for additional educational programs and practical training within the curriculum to enhance awareness and improve preventive measures.

  • Open Access

    Cutaneous mastocytosis: Case report

    by Nemanja P. Čolić, Tanja Z. Lakić, Jelena B. Banjac, Sanja B. Jakovljević, Ljuba M. Vujanović

    Introduction: Mastocytosis is a group of rare diseases characterized by the infiltration and abnormal proliferation of mast cells in various tissues. The disease can have either a benign or malignant form. Symptoms result from the excessive degranulation of mast cells and the release of inflammatory mediators, which can cause hypotension, anaphylaxis, diarrhea, and other systemic symptoms. The clinical picture varies, cutaneous mastocytosis (CM) more commonly occurring in children and often spontaneously regressing, while adults are more likely to develop more aggressive forms of the disease. Case Report: We present a 22-year-old female patient with livid-brown macules that appeared four years ago and progressively spread. Initially, she was diagnosed with acute urticaria and treated with antihistamines and topical corticosteroids without improvement. Due to the persistence of symptoms, in 2024, she consulted a dermatologist, after which she was hospitalized for further diagnostics. The clinical examination indicated a positive Darier sign. Laboratory findings, bone densitometry, chest X-ray, and ultrasound of the upper abdomen were all normal. A skin lesion biopsy revealed mast cell infiltration with an immunohistochemical profile consistent with mastocytosis. Bone marrow biopsy did not indicate systemic mastocytosis. During hospitalization, no medications were prescribed, and the symptoms improved with the application of general measures. Conclusion: CM can also occur in adulthood without the development of the systemic form of the disease. The initial difficulties in recognizing and treating mastocytosis highlight the need for further education of healthcare providers, given the rarity of the disease. With proper education of patients on avoiding triggers and regular use of antihistamines, the disease can be effectively controlled.

  • Open Access

    Tinea incognito: Epilogue of inadequate diagnostics and therapy

    by Srna G. Božić, Nataša Z. Milošević, Aleksandra Bukvić-Šajinović, Dunja M. Vesković, Ljuba M. Vujanović

    Introduction: Tinea incognito is a form of the disease Tinea corporis, and it is a superficial fungal skin infection caused by dermatophytes. It occurs in cases when clinical signs of the condition are misdiagnosed, and treatment with local and/or systemic corticosteroid therapy is administered, leading to the advancement of disease with an altered clinical status that persists for a long time and requires prolonged systemic treatment. Case Report: We present a 71-year-old patient who came for examination due to skin changes that appeared a year ago. The changes were localized on the extensors of the forearm, flexor side of the wrist joint, and lower part of the thighs in the form of erythematous and scaly plaques, partially merged on the forearm, and individual, annular erythematous plaques with pronounced peripheral borders and signs of central regression. The patient was diagnosed with Psoriasis vulgaris. He was treated with systemic retinoids (acitretin, Neotigason caps a 25 mg, Teva B.V.) over the course of 5 months, and with topical corticosteroids (mometazon, Elocom 1 mg/g mast, Organon Heist B.V.) over the course of ten months. Due to the worsening of the local findings, the patient was referred to the Clinic of Dermatovenereology Diseases of the Clinical Center of Vojvodina, where a preliminary diagnosis of Tinea incognito was established. A mycological examination was performed, during which the direct mycological findings were positive. The patient was treated with topical (terbinafine, Lamisil 10 mg/g krem, GSK Consumer Healthcare SARL) and systemic (flukonazol, Diflucan caps a 50 mg, Fareva amboise) antifungals, after which there was complete regression of changes on the skin. Conclusion: Tinea incognito is a superficial fungal skin infection, which occurs due to inadequate therapy prescribed for Tinea corporis. Fungal infections of the skin and skin adnexa are relatively common. Diagnosis is established through a detailed medical history, physical examination, and mycological examination. Timely application of topical and/or systemic antifungals leads to complete regression of skin changes. When the disease goes unrecognized and is treated with inadequate medications, it may progress into a distinct (atypical) form known as Tinea incognito.

  • Open Access

    Sulfasalazine Induced DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome with severe acute hepatitis: Case report

    by Danilo D. Kuzman, Biljana Jeremić-Gajinov, Dunja M. Vesković, Sanja B. Jakovljević, Ljuba M. Vujanović

    Introduction: Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome is a rare and severe form of drug induced delayed-type hypersensitivity reaction with mortality rate up to 10%. It usually manifests with skin rash, fever, lymphadenopathy, hematological abnormalities and involvement of one or more internal organs. Establishing the diagnosis is sometimes late due to variable clinical presentation. Current recommendations for therapy rely mainly on expert opinions, retrospective studies, case reports and series. Sulfasalazine was firstly synthesized in 1930 and is currently being prescribed for various inflammatory and rheumatic diseases. Case report: We present a 45-year-old patient who was prescribed sulfasalazine tablets by a rheumatologist due to reactive arthritis. In the fourth week of therapy, he developed skin rash and fever up to 39.5°C. On admission, generalized maculopapular exanthema covering over 60% of the body surface area, edema of the lower eyelids and bilateral cervical and inguinal lymphadenomegaly were registered. Laboratory findings showed leukocytosis with significant eosinophilia, lymphocytosis, elevated bilirubin values, ALT <100 U/L, while ultrasonography of the upper abdomen confirmed hepatosplenomegaly. The patient was diagnosed with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome using RegiSCAR and J-SCAR diagnostic criteria and systemic therapy with methylprednisolone at a dose of 1.5 mg/kg and other supportive therapy was applied, which resulted in complete regression of the skin changes and normalization of laboratory values. Conclusion: The authors would like to recall the occurrence of Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome as a rare and potentially fatal drug reaction in which awareness of this disease is of key importance for early recognition. Identification of the offending drug followed by a prompt withdrawal and subsequent treatment is essential for decreasing disease related morbidity and mortality and thus we wish to familiarize the sulfasalazine prescribers with this syndrome.

  • Open Access

    Pityriasis lichenoides et varioliformis acuta - dilemmas in diagnosis and choice of therapy: A case report

    by Danilo Kuzman, Ljuba Vujanovic, Dunja Veskovic, Dejan Ogorelica, Aleksandra Fejsa-Levakov

    Introduction. Pityriasis lichenoides et varioliformis acuta is a rare inflammatory skin disease of unknown etiology and its diagnosis is sometimes established by eliminating diseases that are considered in the differential diagnosis. Given the lack of randomized clinical trials, recommendations for therapy remain based on case reports and case series. Case Report. We present a 63-year-old female patient with generalized skin lesions including, papules, papulonecrotic lesions, and atrophic scars accompanied by a subjective feeling of itching that occurred 2 months before admission. The histopathological findings showed a mixed perivascular inflammatory cellular infiltrate and capillary blood vessels with thickened walls in the superficial part of the dermis as signs of vasculitis. The infiltrate was dominated by lymphocytes, neutrophils were admixed, but there were no signs of cellular atypia, which supported the clinical diagnosis of pityriasis lichenoides et varioliformis acuta. Therapy with systemic corticosteroids and doxycycline was applied, which led to the resolution of lesions. Conclusion. The authors would like to bring to the readers’ attention a rare skin disease, pityriasis lichenoides et varioliformis acuta, point to papulonecrotic tuberculids in differential diagnosis due to similar clinical presentation, remind them of the dilemmas that may arise in case of the described lymphocytic vasculitis based on the findings of histopathological analysis, and highlight the effectiveness of doxycycline and prednisone in the therapy.

  • Open Access

    Contact sensitization in patients with chronic venous insufficiency and the impact of the disease duration on the risk of occurrence of contact sensitization

    by Ljuba Vujanovic, Marina Jovanovic, Milan Matic, Sanja Jakovljevic, Zoran Golusin

    Background/Aim. Development of allergic contact dermatitis as a complication of treatment of chronic venous insufficiency is well known. The aim of this study was to determine the incidence of eczematous contact sensitization in patients with chronic venous insufficiency, possible risks for the development of contact sensitization, and the correlation between disease duration and contact sensitization. The working hypothesis was that the incidence of contact sensitivity is significantly higher in individuals with chronic venous insufficiency than in those without chronic venous insufficiency, that they are at greater risk of developing contact sensitization, and that there is a positive correlation between the incidence of contact sensitization and the disease duration. Methods. The study included 266 patients. They were divided into two groups: the study group included patients with chronic venous insufficiency referred for allergy testing due to suspected contact dermatitis, and the control group included patients without chronic venous insufficiency patch tested for suspected contact dermatitis. The severity of chronic venous insufficiency was assessed by CEAP classification. Thereafter, each patient underwent patch testing. Results. The research has shown that the incidence of contact sensitization among patients with chronic venous insufficiency was 49.3%. In these patients, the incidence of contact sensitization to the European standard battery of allergens was 31.55%; to the battery specific for chronic venous insufficiency it was 28.45%. The prevalence of contact sensitization in patients with chronic venous insufficiency was not significantly different from those without chronic venous insufficiency. Conclusion. Patients with chronic venous insufficiency had a 2.45-fold higher risk for developing contact sensitization to two or more allergens, and a 3.69-fold higher risk for developing contact sensitization to five or more allergens compared to those without chronic venous insufficiency. There was a positive correlation between the incidence of contact sensitization and the duration of the disease.